查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1977776

全球膀胱過動症治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Overactive Bladder Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 123 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計膀胱過動症治療市場將從 2025 年的 42.9 億美元成長到 2034 年的 65.7 億美元，2026 年至 2034 年的複合年成長率預計為 4.86%。

全球膀胱過動症（OAB）治療市場正穩定成長，這主要歸因於老年人中泌尿系統疾病盛行率的不斷上升。人們對膀胱健康的日益重視以及診斷方法的進步，都為早期治療提供了支持。藥物治療、神經調節裝置和微創手術等方法被廣泛用於有效控制症狀。

成長要素包括藥物製劑的進步，這些進步提高了安全性並減少了副作用。醫療保險覆蓋範圍的擴大和患者治療需求的增加也促進了市場成長。此外，對新型治療標靶的持續研究正在增強膀胱過動症（OAB）治療產品平臺。

由於聯合療法和創新醫療設備的研發，未來前景十分樂觀。微創治療和居家照護計畫的接受度不斷提高，可望進一步提升病患的依從性。新興市場有望憑藉更完善的醫療基礎設施和日益增強的健康意識實現更高的成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球膀胱過動症治療市場：依疾病類型分類

  • 市場分析、洞察與預測
  • 神經源性膀胱
  • 特發性膀胱

第5章 全球膀胱過動症治療市場：依治療類型分類

  • 市場分析、洞察與預測
  • 藥物治療
  • 肉毒桿菌治療
  • 神經調控
  • 其他治療類型

第6章 全球膀胱過動症症治療市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第7章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第8章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • AbbVie Inc
    • Astellas Pharma Inc
    • Axonics Inc
    • BlueWind Medical
    • Cipla Ltd
    • Endo International Plc
    • Laborie
    • Lupin Ltd
    • Medtronic Plc
    • Merck & Co
    • Pfizer Inc
    • Sumitomo Pharma America Inc.（Urovant Sciences）
    • Teva Pharmaceutical Industries Ltd
    • Viatris Inc
    • Zydus Lifesciences Ltd
簡介目錄
Product Code: VMR112113273

The Overactive Bladder Treatment Market size is expected to reach USD 6.57 Billion in 2034 from USD 4.29 Billion (2025) growing at a CAGR of 4.86% during 2026-2034.

The global overactive bladder (OAB) treatment market is growing steadily due to the rising prevalence of urinary disorders, particularly among the aging population. Increasing awareness about bladder health and improved diagnostic methods are supporting early treatment. Pharmaceutical therapies, neuromodulation devices, and minimally invasive procedures are widely adopted to manage symptoms effectively.

Key growth drivers include advancements in drug formulations with improved safety profiles and reduced side effects. Expanding healthcare coverage and growing patient willingness to seek treatment are also contributing to market expansion. In addition, ongoing research into novel therapeutic targets is strengthening the product pipeline for OAB management.

Future prospects appear promising with the development of combination therapies and innovative medical devices. Increasing acceptance of minimally invasive treatments and home-based management options may further enhance patient compliance. Emerging markets are expected to witness higher growth due to improving healthcare infrastructure and rising awareness levels.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Condition Type

  • Neurogenic Bladder
  • Idiopathic Bladder

By Treatment Type

  • Drug Therapy
  • Botox Treatment
  • Neuromodulation
  • Other Treatment Types

COMPANIES PROFILED

  • AbbVie Inc, Astellas Pharma Inc, Axonics Inc, BlueWind Medical, Cipla Ltd, Endo International plc, Laborie, Lupin Ltd, Medtronic plc, Merck Co, Pfizer Inc, Sumitomo Pharma America Inc Urovant Sciences, Teva Pharmaceutical Industries Ltd, Viatris Inc, Zydus Lifesciences Ltd
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET: BY CONDITION TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Condition Type
  • 4.2. Neurogenic Bladder Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Idiopathic Bladder Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Treatment Type
  • 5.2. Drug Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Botox Treatment Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Neuromodulation Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Other Treatment Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET: BY REGION 2022-2034(USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Condition Type
    • 6.2.2 By Treatment Type
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Condition Type
    • 6.3.2 By Treatment Type
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Condition Type
    • 6.4.2 By Treatment Type
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Condition Type
    • 6.5.2 By Treatment Type
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 South East Asia
    • 6.5.8 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Condition Type
    • 6.6.2 By Treatment Type
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL OVERACTIVE BLADDER TREATMENT INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 AbbVie Inc
    • 8.2.2 Astellas Pharma Inc
    • 8.2.3 Axonics Inc
    • 8.2.4 BlueWind Medical
    • 8.2.5 Cipla Ltd
    • 8.2.6 Endo International Plc
    • 8.2.7 Laborie
    • 8.2.8 Lupin Ltd
    • 8.2.9 Medtronic Plc
    • 8.2.10 Merck & Co
    • 8.2.11 Pfizer Inc
    • 8.2.12 Sumitomo Pharma America Inc. (Urovant Sciences)
    • 8.2.13 Teva Pharmaceutical Industries Ltd
    • 8.2.14 Viatris Inc
    • 8.2.15 Zydus Lifesciences Ltd